Zenas BioPharma's Obexelimab Achieves Highly Significant Phase 3 Success in IgG4-RD, Paving Way for FDA/EMA Submissions

summarizeSummary

Zenas BioPharma announced highly positive results from its registration-directed Phase 3 INDIGO trial for obexelimab in IgG4-RD, meeting all primary and key secondary endpoints, and plans for Q2 2026 FDA submission.

check_boxKey Events

• Obexelimab Phase 3 Trial Success

  Obexelimab met its primary endpoint in the registration-directed Phase 3 INDIGO trial for IgG4-RD, demonstrating a highly statistically significant 56% reduction in flare risk (Hazard Ratio 0.443, p=0.0005).

• Positive Secondary Endpoints & Safety Profile

  The drug also achieved all four key secondary endpoints with high statistical significance and exhibited a favorable safety profile, consistent with prior trials, showing lower serious adverse events and infections compared to placebo.

• Regulatory Submissions Planned

  Zenas BioPharma anticipates submitting a Biologics License Application (BLA) to the U.S. FDA in the second quarter of 2026 and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in the second half of 2026.

• Extended Cash Runway

  The company reported preliminary unaudited cash, cash equivalents, and investments of approximately $360.5 million as of December 31, 2025, which is expected to fund operations through the end of 2026.

auto_awesomeAnalysis

The successful Phase 3 INDIGO trial for obexelimab is a transformative event for Zenas BioPharma, significantly de-risking its lead product candidate and opening a clear path to market for immunoglobulin G4-related disease (IgG4-RD). The strong efficacy data, coupled with a favorable safety profile, positions obexelimab as a potential first-line therapy. This positive clinical milestone, alongside a robust cash runway extending through 2026, strengthens the company's financial position and future growth prospects. Investors should monitor the upcoming BLA/MAA submissions and the ongoing discussions regarding the Royalty Pharma milestone.